School of Medicine

Wayne State University School of Medicine

Fingolimod PPMS- Oral Pill Study Sponsored by Novartis for the Treatment of Primary Progressive Multiple Sclerosis Closed to Enrollment

This study is a 3 year multi-center study comparing the safety and efficacy of fingolimod in patients with primary progressive Multiple Sclerosis (PPMS). Patients will be randomly assigned to receive a daily tablet of either 0.5 mg fingolimod or placebo (dummy pill).

Eligibility: Patients 25-65 yrs old with PPMS, able to walk at least 100 meters with or without resting, if assistance is needed for walking that assistance may only come from a cane or a crutch.
For more information visit: Novartis PPMS